Sector Market Growth in Legalization of Cannabis

NEW YORK, July 27, 2017 /PRNewswire/ --

The legal cannabis market is growing at a rapid pace due to the legalization in certain states in USA. According to a report published by Grand View Research, the global medical cannabis market is expected to reach $55.8 billion by 2025, with a compound annual growth rate of 17.1 percent during the forecasted period. The growing adoption of cannabis products is a major factor that drives the growth of the market. Currently, eight states have legalized recreational cannabis and 29 states have allowed cannabis for medical use. ChineseInvestors.com, Inc. (OTC: CIIX), MCig Inc. (OTC: MCIG), MassRoots, Inc. (OTC: MSRT), Cannabis Science, Inc. (OTC: CBIS), Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP).

Cannabidiol, one of active cannabinoids identified in the cannabis plant, is considered to have significant medical benefits. According to Hemp Business Journal and Vote Hemp, sale of Hemp CBD was $130 million in 2016, with a growth rate of 53% AGR or 'Adjusted Growth Revenue'. Eric Steenstra, President of Vote Hemp stated: "To date, 31 states have passed legislation that allows hemp farming per provisions set forth in the 2014 Farm Bill, and the U.S. remains the largest consumer market for hemp products worldwide. We need Congress to pass federal legislation to allow commercial hemp farming nationally, to let our farmers and American business take advantage of the robust economic opportunity hemp provides."

ChineseInvestors.com, Inc. (OTCQB: CIIX) announced earlier this week that, "its wholly-owned foreign enterprise, CBD Biotechnology Co. Ltd., has officially filed a record of its first line of non-industrial hemp-infused skin care products with the China Food and Drug Administration (CFDA). The new 'CBD Magic Hemp Series' skin care line is expected to launch between late August and early September 2017, positioning CBD Biotechnology as a first-mover in an untapped segment of China's skin care industry."

Recognizing the untapped market potential, CBD Biotechnology is developing and manufacturing what it believes to be the first line of non-industrial hemp-infused skin care products in China in hopes of educating the Chinese population on the potential benefits of CBD for skin care. "I am very pleased to announce the upcoming launch of CBD Biotechnology's non-industrial hemp-infused skin care line," says Summer Yun, CEO of CBD Biotechnology Co., Ltd. "As one of the first skin care products containing CBD extract marketed in China, CBD Magic Hemp Series expects to capture 100% of China's market share in this novel skin care products category. Although a catalogue published by the CFDA, indicates that cannabis sativa leaf extract can legally be added to skin care products, it appears that Chinese skin care manufacturers have not yet entered this market, enabling CBD Biotechnology's skin care products to proudly take the lead with its innovative product line."

The 'CBD Magic Hemp Series' will include: - The CBD Peptide Collagen Solution - intended to moisturize and firm the skin, while smoothing fine lines, and preventing premature aging; - The CBD Perfecting Shield Primer - intended to even skin tone, while covering fine lines and minimizing the look of pores; and - The CBD Brightening and Refreshing Moisturizer - intended to balance the skin's moisture, while forming a protective, moisturizing layer.

"Consumption of skin care products per capita in China has increased from 169 Chinese Yuan Renminbi to 352CNY during the last five years," says Yun. "China has the world's second largest consumer market for skin care products, with its current market size already exceeding 300 billion CNY. The CAGR (compound annual growth rate) of the skin care products market in China is 9.1%, more than double the global average of 4.1%. CBD Biotechnology will benefit from this large consumer market in China becoming one of the first companies in China to infuse its skin care products CBD extracted from non-industrial hemp."

mCig Inc. (OTCQB: MCIG) is a diversified and vertically integrated cannabis group committed to being the leading distributor of technology, products and services to fit the needs of the rapidly expanding cannabis sector. The company recently announced the latest project updates for Grow Contractors, in addition to the latest expansion of its cannabis supply division into the California cannabis market with record sales driven by recent recreational legalization in Nevada. Robert Kressa, CEO of Grow Contractors, said: "Grow Contractors is doing exceptionally well, building faster and taking on more projects, with years of growth ahead. The recent influx of requests in Nevada alone will keep us busy in the foreseeable future. Nevada will be working many years to fulfill the demands of this budding industry, and Grow Contractors will be there to support and provide service along the way," 

MassRoots, Inc. (OTCQB: MSRT) is one of the largest technology platforms for the regulated cannabis industry. Recently, the company announced that it has executed a Definitive Agreement for MassRoots to acquire Odava for cash and shares of MassRoots' common stock. Odava is an industry-leading platform technology that provides compliance, point-of-sale, and supply chain management for the cannabis industry. The combination of the two companies is expected to create one of the largest technology conglomerates in the cannabis market and now will also be providing regulatory compliance, point-of-sale and consumer engagement programs for the entire industry.

Cannabis Science, Inc. (OTC: CBIS) is a U.S. company specializing in the development of cannabinoid-based medicines. The company recently announced that it has found a California facility ideal for its large-scale manufacturing and product distribution center as it ramps up its efforts to supply cannabinoid medications in high-demand by self-medicating patients. As Nevada's Governor issues a Statement of Emergency due to the potential of limited cannabis availability, CBIS is actively looking for a similar facility in Nevada.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is a Phase 3 clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, anabasum, is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. The company recently announced that safety and efficacy data from its previously completed Phase 2 clinical study of anabasum or formerly known as JBT-101, the treatment of diffuse cutaneous systemic sclerosis was presented at the European League Against Rheumatism Annual Meeting in Madrid, Spain. The presentation included a review of the Phase 2 topline data previously announced, additional data from the study regarding Patient-Reported Outcomes Measurement Information System (PROMIS)-29, and additional analysis of the previously-reported CRISS domains and transcriptome data.

Please Sign Up Now at http://www.FinancialBuzz.com to Receive Alerts on Trending Financial News from all these companies. 'The Latest Buzz in Financial News'

Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com  

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions as we purely incorporate public market research along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. We also do not include any personal opinions or commentary. For this release, FinancialBuzz.com expects to be compensated three thousand dollars for financial news dissemination and PR services by chineseinvestors.com inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com has signed a two year agreement with chineseinvestors.com inc. for one hundred thousand restricted common shares for continued financial news dissemination and PR services. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, and quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.

For further information:
Media Contact:
[email protected]
+1-877-601-1879

SOURCE FinancialBuzz.com